A recent study suggests that people who stop using popular weight-loss injections like Mounjaro or Wegovy may regain reduced body mass much more quickly than those who halt traditional lifestyle regimens.
Findings released in a leading medical journal demonstrates that while obese people often shed substantial amounts of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month after stopping.
"Users buying these medications must be informed of the risk of quick weight regain when the therapy concludes," cautioned researcher Dr. Susan Jebb.
That rate of regain suggests a return to pre-treatment weight within about 18 months.
Analyzing Treatments
The research, which reviewed dozens of trials involving thousands of patients, contrasted the outcomes of the injectable medications with other pills.
Scientists emphasize that people who shed pounds through dieting typically experience a less rapid creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Experts suggest the mode of action of the jabs explains the heightened weight return.
GLP-1 drugs imitate a natural hormone called GLP-1, which controls appetite.
"Artificially providing the hormone levels far above than the body's typical production could lead to the system to produce less of its own natural hormone, and may also reduce sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this medication results in hunger is unsuppressed, making overeating far more likely."
An Ongoing Issue?
The NHS suggest the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, considering the significant potential of relapse, the treatment might need to be long-term.
This perspective is supported by pharmaceutical companies, who state that the results "underscore the chronic nature of obesity," comparing it to managing conditions like diabetes.
User Testimonies
People who have stopped the medication explain a powerful resurgence of hunger.
"I experienced a switch activating and you're instantly extremely hungry," recalled a patient.
This difficulty is worsened if users have not adopted lasting lifestyle or habit modifications during treatment.
Widespread Adoption
Figures show that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high.
- Use is greater among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, researchers caution that while the jabs are potent agents for weight loss, they are not a standalone cure and long-term success relies on integrated behavioural management.
